Publications

Search ACTG publications from 1/1/2006 to current.

Search

Filter results by

Found 747 results
Found 747 results.
Skip Alphabet Links A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  

E

Erlandson KM, Wu K, Koletar SL, et al. "Association Between Frailty and Components of the Frailty Phenotype With Modifiable Risk Factors and Antiretroviral Therapy." J. Infect. Dis.. 2017;215(6):933-937.
Erlandson KM, Kitch D, C Wester W, et al. "The Impact of Statin and Angiotensin-Converting Enzyme Inhibitor/Angiotensin Receptor Blocker Therapy on Cognitive Function in Adults With Human Immunodeficiency Virus Infection." Clin. Infect. Dis.. 2017;65(12):2042-2049.
Erlandson KM, Fiorillo S, Masawi F, et al. "Antiretroviral initiation is associated with increased skeletal muscle area and fat content." AIDS. 2017;31(13):1831-1838.
Erlandson KM, Taejaroenkul S, Smeaton L, et al. "A Randomized Comparison of Anthropomorphic Changes With Preferred and Alternative Efavirenz-Based Antiretroviral Regimens in Diverse Multinational Settings." Open Forum Infect Dis. 2015;2(3):ofv095.
Erlandson KM, Perez J, Abdo M, et al. "Frailty, Neurocognitive Impairment, or Both in Predicting Poor Health Outcomes Among Adults Living With Human Immunodeficiency Virus." Clin. Infect. Dis.. 2019;68(1):131-138.
Erlandson KMace, Kitch D, Tierney C, et al. "Impact of randomized antiretroviral therapy initiation on glucose metabolism." AIDS. 2014;28(10):1451-61.
Eron JJ, Bosch RJ, Bettendorf D, Petch L, Fiscus S, Frank I. "The effect of lamivudine therapy and M184V on the antiretroviral activity of didanosine." J. Acquir. Immune Defic. Syndr.. 2007;45(2):249-51.
Eron JJ, Park J-G, Haubrich R, et al. "Predictive value of pharmacokinetics-adjusted phenotypic susceptibility on response to ritonavir-enhanced protease inhibitors (PIs) in human immunodeficiency virus-infected subjects failing prior PI therapy." Antimicrob. Agents Chemother.. 2009;53(6):2335-41.
Eshleman SH, Hudelson SE, Redd AD, et al. "Analysis of genetic linkage of HIV from couples enrolled in the HIV Prevention Trials Network 052 trial." J. Infect. Dis.. 2011;204(12):1918-26.
Evans SR, Fichtenbaum CJ, Aberg JA. "Comparison of direct and indirect measurement of LDL-C in HIV-infected individuals: ACTG 5087." HIV Clin Trials. 2007;8(1):45-52.
Evans SR, Simpson DM, Kitch DW, et al. "A randomized trial evaluating Prosaptide for HIV-associated sensory neuropathies: use of an electronic diary to record neuropathic pain." PLoS ONE. 2007;2(6):e551.
Evans SR, Clifford DB, Kitch DW, et al. "Simplification of the research diagnosis of HIV-associated sensory neuropathy." HIV Clin Trials. 2008;9(6):434-9.
Evans SR, Yeh T-min, Sacktor N, et al. "Selegiline transdermal system (STS) for HIV-associated cognitive impairment: open-label report of ACTG 5090." HIV Clin Trials. 2007;8(6):437-46.
Evans SR, Lee AJ, Ellis RJ, et al. "HIV peripheral neuropathy progression: protection with glucose-lowering drugs?" J. Neurovirol.. 2012;18(5):428-33.
Evans SR, Ellis RJ, Chen H, et al. "Peripheral neuropathy in HIV: prevalence and risk factors." AIDS. 2011;25(7):919-28.

F

Ferreira MAR, Mangino M, Brumme CJ, et al. "Quantitative trait loci for CD4:CD8 lymphocyte ratio are associated with risk of type 1 diabetes and HIV-1 immune control." Am. J. Hum. Genet.. 2010;86(1):88-92.
Fichtenbaum CJ, Yeh T-min, Evans SR, Aberg JA. "Treatment with pravastatin and fenofibrate improves atherogenic lipid profiles but not inflammatory markers in ACTG 5087." J Clin Lipidol. 2010;4(4):279-87.
Fichtenbaum CJ, Evans SE, Aberg JA. "High-sensitivity C-reactive protein levels do not decrease with the use of statins in all persons with HIV infection." AIDS. 2011;25(16):2053.
Fife KH, Wu JW, Squires KE, D Watts H, Andersen JW, Brown DR. "Prevalence and persistence of cervical human papillomavirus infection in HIV-positive women initiating highly active antiretroviral therapy." J. Acquir. Immune Defic. Syndr.. 2009;51(3):274-82.
Figueroa DB, Madeen EP, Tillotson J, et al. "Genetic Variation of the Kinases That Phosphorylate Tenofovir and Emtricitabine in Peripheral Blood Mononuclear Cells." AIDS Res. Hum. Retroviruses. 2018;34(5):421-429.
Firnhaber C, Smeaton L, Saukila N, et al. "Comparisons of anemia, thrombocytopenia, and neutropenia at initiation of HIV antiretroviral therapy in Africa, Asia, and the Americas." Int. J. Infect. Dis.. 2010;14(12):e1088-92.
Firnhaber C, Smeaton LM, Grinsztejn B, et al. "Differences in antiretroviral safety and efficacy by sex in a multinational randomized clinical trial." HIV Clin Trials. 2015;16(3):89-99.
Fischl MA, Collier AC, A Mukherjee L, et al. "Randomized open-label trial of two simplified, class-sparing regimens following a first suppressive three or four-drug regimen." AIDS. 2007;21(3):325-33.
Fiscus SA, Cu-Uvin S, Eshete ATilahun, et al. "Changes in HIV-1 subtypes B and C genital tract RNA in women and men after initiation of antiretroviral therapy." Clin. Infect. Dis.. 2013;57(2):290-7.
Flexner C. "HIV drug development: the next 25 years." Nat Rev Drug Discov. 2007;6(12):959-66.
Flexner C, Tierney C, Gross R, et al. "Comparison of once-daily versus twice-daily combination antiretroviral therapy in treatment-naive patients: results of AIDS clinical trials group (ACTG) A5073, a 48-week randomized controlled trial." Clin. Infect. Dis.. 2010;50(7):1041-52.
Foulkes AS, Wohl DA, Frank I, et al. "Associations among race/ethnicity, ApoC-III genotypes, and lipids in HIV-1-infected individuals on antiretroviral therapy." PLoS Med.. 2006;3(3):e52.
Foulkes AS, DeGruttola VG. "A resampling-based approach to multiple testing with uncertainty in phase." Int J Biostat. 2007;3(1):Article 2.
Freeman ML, Lederman MM, Gianella S. "Partners in Crime: The Role of CMV in Immune Dysregulation and Clinical Outcome During HIV Infection." Curr HIV/AIDS Rep. 2016;13(1):10-9.
Freeman ML, Shive CL, Nguyen TP, Younes S-A, Panigrahi S, Lederman MM. "Cytokines and T-Cell Homeostasis in HIV Infection." J. Infect. Dis.. 2016;214 Suppl 2:S51-7.

Pages